Business Description
Takara Bio Inc
ISIN : JP3460200003
Share Class Description:
FRA:TF2: Ordinary SharesTotal Employee Number:
1,779Description
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.86 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -3.33 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.63 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.8 | |||||
3-Year Book Growth Rate | -2.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 49.57 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.84 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.08 | |||||
9-Day RSI | 42.59 | |||||
14-Day RSI | 46.38 | |||||
3-1 Month Momentum % | -1.65 | |||||
6-1 Month Momentum % | 51.02 | |||||
12-1 Month Momentum % | 34.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.76 | |||||
Quick Ratio | 4.27 | |||||
Cash Ratio | 2.63 | |||||
Days Inventory | 228.86 | |||||
Days Sales Outstanding | 90.49 | |||||
Days Payable | 26.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -6.7 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.25 | |||||
Operating Margin % | -11.62 | |||||
Net Margin % | -23.81 | |||||
EBITDA Margin % | -8.18 | |||||
FCF Margin % | -22.63 | |||||
OCF Margin % | 9.18 | |||||
ROE % | -9.03 | |||||
ROA % | -7.37 | |||||
ROIC % | -4.44 | |||||
3-Year ROIIC % | -50.18 | |||||
ROC (Joel Greenblatt) % | -11.2 | |||||
ROCE % | -7.05 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 35.09 | |||||
Shiller PE Ratio | 24.51 | |||||
PS Ratio | 3.42 | |||||
PB Ratio | 1.33 | |||||
Price-to-Tangible-Book | 1.74 | |||||
Price-to-Operating-Cash-Flow | 38.45 | |||||
EV-to-EBIT | -14.92 | |||||
EV-to-Forward-EBIT | 39.31 | |||||
EV-to-EBITDA | -39 | |||||
EV-to-Forward-EBITDA | 25.57 | |||||
EV-to-Revenue | 3.19 | |||||
EV-to-Forward-Revenue | 6.04 | |||||
EV-to-FCF | -14.26 | |||||
Price-to-GF-Value | 1.33 | |||||
Price-to-Projected-FCF | 1.48 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
| Price-to-Net-Current-Asset-Value | 9.3 | |||||
Earnings Yield (Greenblatt) % | -6.7 | |||||
FCF Yield % | -6.55 | |||||
Forward Rate of Return (Yacktman) % | -35.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Takara Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 228.085 | ||
| EPS (TTM) (€) | -0.455 | ||
| Beta | 0.7235 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.65 | ||
| Volatility % | 47.12 | ||
| 14-Day RSI | 46.38 | ||
| 14-Day ATR (€) | 0.011509 | ||
| 20-Day SMA (€) | 5.9675 | ||
| 12-1 Month Momentum % | 34.01 | ||
| 52-Week Range (€) | 3.84 - 6.1 | ||
| Shares Outstanding (Mil) | 120.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takara Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takara Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| JPY 17.000000 Cash Dividend | 2025-03-28 | 4.98 (-1.39%) | ||
| 400:1 Stock Split | 2011-03-29 | 5.14 (+0.00%) |
Show
Entries
Takara Bio Inc Frequently Asked Questions
What is Takara Bio Inc(FRA:TF2)'s stock price today?
The current price of FRA:TF2 is €5.95. The 52 week high of FRA:TF2 is €6.10 and 52 week low is €3.84.
When is next earnings date of Takara Bio Inc(FRA:TF2)?
The next earnings date of Takara Bio Inc(FRA:TF2) is .
Does Takara Bio Inc(FRA:TF2) pay dividends? If so, how much?
Takara Bio Inc(FRA:TF2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Takara Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers